Related by context. All words. (Click for frequent words.) 71 varicella infection 68 CMV infection 67 ALT flares 67 quadrivalent vaccine 66 FluCAM arm 66 arterial thromboembolic events 66 TEAEs 66 C. diff infections 66 pH#N# 66 hepatitis C genotype 66 Aspergillus infections 65 ertapenem 65 neutropenic fever 65 postexposure prophylaxis 65 pneumococcal infection 65 HIB vaccine 65 acellular pertussis DTaP 65 chlamydial infections 65 PPSV# 65 serogroup C 65 RSV infections 65 recurrent VTE 64 neurologic complications 64 myopericarditis 64 trivalent inactivated influenza 64 de aths 64 antibody titers 64 antiviral prophylaxis 64 external genital lesions 64 MenACWY CRM 64 S. aureus infection 64 severe rotavirus gastroenteritis 64 4CMenB 64 febrile illness 64 vaccine serotypes 64 HAV infection 64 nonvaccine 64 HBeAg negative 64 S. aureus isolates 64 pneumococcal serotypes 63 Pneumococcal pneumonia 63 hemorrhagic cystitis 63 recurrent UTI 63 elevated ALT 63 definite stent thrombosis 63 hepatitis B infection 63 transaminase elevations 63 LTBI 63 adverse reactions occurring 63 corticosteroid therapy 63 Guillain Barré 63 serogroups 63 varicella chickenpox 63 syncopal 63 acute respiratory tract infections 63 renal toxicity 63 MCV4 63 myopathy rhabdomyolysis 63 paralytic poliomyelitis 63 genital herpes infections 63 susceptible isolates 63 COPD exacerbation 63 HIV uninfected 63 postvaccination 63 seropositivity 63 invasive aspergillosis 63 lymphocytosis 63 elevated bilirubin 63 Pediarix 63 serum antibody 63 bacterium Neisseria meningitidis 63 aseptic meningitis 62 prolonged QT interval 62 virologic failure 62 pneumococcal pneumonia 62 MMR vaccinations 62 hematologic toxicity 62 serologic testing 62 candidemia 62 seroconverted 62 nonpregnant women 62 Pentacel vaccine 62 sexually transmitted HPV 62 invasive Hib 62 intravenous bisphosphonates 62 polysaccharide vaccines 62 reactogenicity 62 anti HBs 62 NNRTI resistance 62 paralytic polio 62 recurrent wheezing 62 chlamydial infection 62 HPV subtypes 62 S. aureus infections 62 DTaP vaccine 62 neutropaenia 62 gonococcal infections 62 asthma exacerbations 62 HBV infections 62 relapsed MM 62 rebleeding 62 seroconversion 62 PASI scores 62 evaluable subjects 62 Postoperative complications 62 MRSA isolates 62 aldosterone antagonist 62 Infusion Reactions Severe 62 leukopenia 61 asthma exacerbation 61 APTIVUS r 61 fetal chromosomal 61 quadrivalent 61 malignant neoplasm 61 advanced adenoma 61 humoral responses 61 serogroup B 61 HBeAg negative patients 61 palivizumab 61 myocardial infarctions MIs 61 Staphylococcus aureus infections 61 tipranavir ritonavir 61 PCV7 vaccine 61 advanced neoplasia 61 postexposure 61 vasogenic edema 61 inhospital 61 febrile convulsions 61 BSIs 61 im peramivir 61 ribavirin therapy 61 severe exacerbations 61 interstitial pneumonia 61 nonmelanoma skin cancers 61 dysglycemia 61 Vibrio infections 61 trivalent influenza vaccine 61 prelicensure 61 HBeAg seroconversion 61 gonococcal infection 61 serotype #A 61 TNF antagonist 61 pneumococci 61 C difficile infection 61 orchitis 61 acid suppressive medication 61 neurologic sequelae 61 poor metabolizers 61 adverse cytogenetics 61 endometrial hyperplasia 61 seroprotection 61 varicella vaccine 61 hepatorenal syndrome 61 anemia hemoglobin 61 intranasal mist 61 enterovirus infection 61 precancerous cervical lesions 61 immuno compromised patients 61 CMV disease 61 hypophosphatemia 61 endophthalmitis 61 MRSA colonization 61 serum creatinine levels 61 HPV-#/# 61 oral poliovirus 60 Bloodstream infections 60 persistent wheezing 60 TMP SMX 60 CIN3 60 recurrent venous thromboembolism 60 RSV hospitalizations 60 severe hypersensitivity reactions 60 virological failure 60 malignant neoplasms 60 fetal malformations 60 ano genital warts 60 dose cohort 60 Clostridium difficile infections 60 PREZISTA r arm 60 antibody titer 60 intracranial hemorrhage ICH 60 ADEs 60 bacteraemia 60 nonsevere 60 corneal infection 60 spontaneous preterm delivery 60 Chlamydia infection 60 chronic HBV 60 MenB 60 monoinfected patients 60 febrile seizure 60 NATRECOR ® 60 nonpregnant adults 60 severe asthma exacerbations 60 nonvaccine serotypes 60 Immune responses 60 febrile seizures 60 PREZISTA r 60 Febrile neutropenia 60 Hib vaccines 60 eczema vaccinatum 60 diphtheria tetanus acellular pertussis 60 neutrophil counts 60 bacterial pneumonias 60 neuropsychiatric events 60 abnormal Pap smear 60 KRAS mutations occur 60 C diff infection 60 HIV HCV coinfected 60 WNV infections 60 chemoprophylaxis 60 thrombocytopenic 60 Twinrix 60 aged ≥ 60 EBV infection 60 bacteriuria 60 venous blood clots 60 pneumococcal infections 60 Influenza vaccination 60 tetanus boosters 60 gonococcal 60 Hib disease 60 generalized edema 60 pneumococcal conjugate 60 Hib meningitis 60 cervical intraepithelial neoplasia 60 ovarian hyperstimulation syndrome OHSS 60 osteosarcomas 60 anagrelide 60 patients evaluable 60 anaphylactic reactions 60 seroprotective 60 chronic GVHD 60 ZOSTAVAX 60 Complication rates 60 leucopenia 60 autoimmune reactions 60 poliovirus vaccine 60 inactivated poliovirus 60 vWD 60 7 valent pneumococcal 60 virologic breakthrough 60 fluvastatin 60 GnRH agonists 60 Novartis MenB vaccine 60 transfusion transmitted 60 neurodevelopmental impairment 60 tetanus diptheria 60 visceral metastases 60 Listeria infections 60 intensive statin therapy 60 BARACLUDE ® 60 generalized vaccinia 59 grade cervical intraepithelial 59 salmeterol HFA MDI 59 VAERS 59 HBeAg positive 59 abnormal Pap test 59 discontinued Viread 59 hypersensitivity reactions 59 CA MRSA infections 59 invasive meningococcal disease 59 HER2 positive cancers 59 mucosal inflammation 59 mumps rubella 59 KINRIX 59 pyelonephritis 59 renal flares 59 hypercalcemia 59 dengue hemorrhagic fever DHF 59 elevated LDH 59 febrile neutropenia 59 micafungin 59 BCG vaccinated 59 SCIg 59 upper gastrointestinal bleeding 59 antimicrobial prophylaxis 59 hematologic adverse 59 acellular pertussis vaccine 59 Menactra vaccine 59 NEUPOGEN 59 coinfection 59 Varicella chicken pox 59 CMV infections 59 atopic disorders 59 diphtheria toxoid 59 oxycodone CR 59 meningococcal conjugate vaccine 59 Asymptomatic 59 % CI #.#-#.# [007] 59 COPD exacerbations 59 Hepatotoxicity 59 DPT vaccine 59 receiving XGEVA 59 inactivated influenza vaccine 59 metastatic lung cancer 59 mcg albinterferon alfa 2b 59 imipenem 59 bovine thrombin 59 atopic sensitization 59 serious pneumococcal infections 59 protease inhibitors PIs 59 pertussis vaccination 59 bolus dose 59 herpes zoster shingles 59 serotypes strains 59 PSA nadir 59 neutropenia dehydration dyspnea 59 nonvertebral fractures 59 PCV# 59 rFVIIa 59 anaphylactoid reactions 59 HbA 1c levels 59 rhinovirus infections 59 polysaccharide vaccine 59 rotaviruses 59 receiving VICTRELIS 59 mg kg dose 59 amoxicillin clavulanate 59 QTc prolongation 59 hypoglycemic episodes 59 HIV coinfected 59 gout flare 59 leukemic transformation 59 genital ulcer disease 59 mucocutaneous reactions 59 polyp recurrence 59 gadobutrol 59 elevated triglyceride levels 59 seronegative 59 varicella vaccines 59 Haemophilus influenzae 59 mycophenolate 59 eosinophilic pneumonia 59 tetanus diphtheria acellular pertussis 59 cobiprostone 59 adverse reactions 59 glycated hemoglobin levels 59 angioneurotic edema 59 KETEK 59 colorectal adenoma 59 VZV 59 oseltamivir resistant 59 certolizumab 59 BLLs 59 strep infections 59 postoperative infections 59 serous ovarian cancer 59 rhinovirus infection 59 Tysabri infusions 59 moderately emetogenic 59 RLS sufferers 59 herpes zoster vaccine 59 MMRV vaccine 59 asymptomatic carriers 59 oncogenic HPV types 59 chorioamnionitis 59 cervical vulvar 59 invasive candidiasis 59 immunopathology 59 poorly immunogenic 59 % CI #.#-#.# [003] 59 atrophic gastritis 59 latent tuberculosis infection 59 pneumococcal vaccination 59 hemorrhagic complications 59 virologic failures 59 fosamprenavir 59 hypersensitivity allergic reactions 59 pertussis Tdap vaccine 59 N. meningitidis 59 immunosuppressed patients 59 concomitant antibiotics 59 laboratory abnormalities 59 Serious adverse reactions 59 ocular toxicity 59 posaconazole 59 hepatic failure 59 varicella 59 Rimantadine 59 microbial keratitis 59 Engerix B 59 HER2 overexpression 59 histological subtype 59 influenzalike illness 59 Partial Responses 59 microbiologically evaluable 59 Opportunistic infections 59 HPV genotypes 59 biochemical relapse 59 GBA mutations 59 chronic HCV genotype 59 ruptured aneurysms 59 tuberculin skin testing 58 enterocolitis 58 NNT = 58 renal scarring 58 acromegalic patients 58 CP CPPS 58 empyema 58 microscopic hematuria 58 MMRV 58 Peripheral edema 58 treatment emergent AEs 58 ALT elevations 58 events SAEs 58 Pneumococcal vaccine 58 neonatal sepsis 58 rotavirus diarrhea 58 GH deficiency 58 intravitreal injections 58 diarrheal deaths 58 advanced adenomas 58 invasive pneumococcal infections 58 liver transplantations 58 immunocompromised individuals 58 CCR5 tropic 58 acute rhinosinusitis 58 thrombotic events 58 URTI 58 tetanus measles 58 superinfection 58 adenomatous polyps 58 Acinetobacter infections 58 null responder 58 bacterial sepsis 58 invasive MRSA infections 58 b Hib 58 Virologic failure 58 NAbs 58 chickenpox vaccinations 58 CVD mortality 58 dalteparin 58 cryptococcal meningitis 58 MenC 58 UGT#A# * 58 hyperbilirubinemia 58 MCyR 58 virologic responses 58 tetanus toxoid 58 thrombotic complications 58 WNV encephalitis 58 montelukast 58 HCV antibody 58 penicillin allergy 58 cerebrovascular events 58 cervical lesions 58 IGFD 58 argatroban 58 ARCOXIA 58 achieved ACR# 58 FOLFIRI alone 58 causative pathogen 58 log# reduction 58 pertussis immunization 58 Menomune 58 anal cancers 58 amenorrhoea 58 untreated celiac disease 58 Skin rashes 58 rotavirus infection 58 follicular lymphomas 58 staphylococcal infections 58 BI/NAP#/# 58 perioperative complications 58 ARCALYST ® 58 pertussis tetanus 58 Hypotension 58 chronic urticaria 58 nosocomial infection 58 idraparinux 58 enteroviruses 58 dysmenorrhoea 58 MGd 58 revascularizations 58 noncardiac 58 corticosteroid dose 58 biologic DMARD 58 PCNSL 58 mcg dL 58 NNRTI resistant virus 58 Measles Mumps 58 diptheria tetanus 58 injectable influenza 58 abnormal Pap smears 58 enteroviral infection 58 oncogenic HPV 58 HBsAg 58 Renal impairment 58 P. falciparum malaria 58 empiric therapy 58 % CI #.#-#.# [008] 58 del 5q MDS 58 fluoroquinolone resistant 58 varicella chicken pox 58 genotypic resistance 58 abnormal cytology 58 systemic corticosteroids 58 macrovascular events 58 de novo AML 58 TDF FTC 58 PPSV 58 ESBL producing E. coli 58 myocardial infarctions 58 incidence ≥ 58 mesotheliomas 58 S aureus 58 hepatotoxicity 58 genital ulcers 58 CD# upregulation 58 slow metabolizers 58 melanoma lesions 58 undetectable hepatitis C 58 recurrent glioblastoma multiforme 58 T1DM 58 Hib vaccination 58 Bacillus Calmette Guerin BCG 58 shingles herpes zoster 58 VTEs 58 nonvertebral fracture 58 mcg kg REBETOL 58 octreotide LAR 58 neutropenic sepsis 58 basal cell carcinomas 58 recurrent genital herpes 58 solifenacin 58 serum aminotransferase levels 58 toxoid 58 Subgroup analyzes 58 transfusion syndrome 58 rotavirus gastroenteritis 58 receiving Vectibix monotherapy 58 serum urate levels 58 MGUS 58 foodborne infections 58 fluoroquinolone resistance 58 SMZ TMP 58 ORENCIA ® 58 MenACWY 58 HCV infections 58 mcg dose 58 hematological toxicities 58 venous thromboembolisms 58 skeletal metastases 58 pathologic fractures 58 suboptimal adherence 58 linezolid resistant 58 NOMID 58 gastrointestinal bleeds 58 Balamuthia 58 Adverse reactions 58 underwent resection 58 Pentacel R 58 orofacial clefts 58 immunological responses 58 nondiabetic patients 58 thromboembolic 58 liver transplant recipients 58 Human papilloma virus 58 placebo controlled clinical trials 58 parasitemia 58 MMR measles mumps rubella 58 intravenous vancomycin 58 venom immunotherapy 58 quadrivalent human papillomavirus 58 stent thromboses 58 HBeAg 58 CANCIDAS 58 Varicella 58 retrospective cohort 58 anterior uveitis 58 recurrent ischemic stroke 58 hydroxyvitamin D levels 58 hyperacute 58 ritonavir boosted lopinavir 58 Myelosuppression 58 gemifloxacin 58 rubella vaccine MMR 58 bacteremia 58 receiving VELCADE 58 invasive fungal infection 58 ofpatients 58 influenza antiviral medications 58 MMR measles mumps 58 perioperatively 57 CCR5 tropic HIV 57 oral prednisolone 57 gastrointestinal perforations 57 venous thromboembolic events 57 decompensated liver disease 57 tipranavir r 57 HPV Human Papillomavirus 57 Pegasys peginterferon alfa 2a 57 dapsone 57 neutropenic 57 Fluzone vaccine 57 NRTI resistance 57 splenectomized patients 57 serum IGF 57 SGPT 57 dengue haemorrhagic fever DHF 57 LAIV 57 nonexposed 57 acute gout flares 57 noncardiovascular mortality 57 cervical vaginal 57 elevated LDL cholesterol 57 postoperative infection 57 antibiotic prophylaxis 57 complete cytogenetic response 57 IgG2 57 cervical HPV 57 HGPIN 57 ddI 57 pyrexia mucositis sepsis febrile 57 allergic sensitization 57 invasive pneumococcal diseases 57 cerebral vasospasm 57 Adverse effects 57 neoplasias 57 methicillin resistant staph 57 thromboembolic complications 57 MF# adjuvanted 57 rizatriptan 57 radioiodine therapy 57 severely immunocompromised patients 57 treatment naive genotype 57 parous women 57 opportunistic pathogens 57 SSTIs 57 EDSS scores 57 atypical ductal hyperplasia 57 PCV7 57 nonadherent 57 β blockers 57 cytomegalovirus infection 57 pentoxifylline 57 testicular tumors 57 ARIs 57 antibody titres 57 psychiatric comorbidities 57 discontinuations due 57 receiving immunosuppressive therapy 57 perimenopausal women 57 recurrent DVT 57 trimethoprim sulfamethoxazole 57 alemtuzumab treated 57 CMV reactivation 57 C. difficile infections 57 IgM antibodies 57 CRBSIs 57 chlamydial 57 virologically 57 infective endocarditis 57 pyridostigmine 57 hemagglutination inhibition 57 Ribavirin causes 57 carbapenem resistant 57 Fluzone Intradermal 57 LV dysfunction 57 pertusis 57 HbA1C levels 57 atazanavir ritonavir 57 histologic subtype 57 lymphopenia 57 receiving ISENTRESS 57 genotype 1b 57 Adverse events 57 HCV genotype 57 generalized tonic clonic seizures 57 SRBD 57 tigecycline 57 anemia leukopenia 57 alanine aminotransferase 57 WNV infection 57 salmeterol fluticasone 57 nevirapine Viramune 57 canakinumab 57 Tetanus diphtheria 57 atypical femur fractures 57 methimazole 57 low expressors 57 cephalosporin antibiotics 57 pre eclamptic 57 lipid lowering medication 57 antibody responses 57 clomipramine 57 thyrotropin levels 57 ß blockers 57 congenital CMV 57 HCV infection 57 basal cell nevus syndrome 57 anaphylactic reactions bronchospasm 57 HAART initiation 57 non hematological toxicities 57 prescribed statins 57 Diamyd r 57 postoperative complication 57 herpesviruses 57 GABHS 57 prodromal symptoms 57 PegIFN RBV 57 antiepileptic drugs AEDs 57 EXJADE 57 neurologic outcomes 57 gestational hypertension 57 endometrial carcinoma 57 heavily pretreated 57 Erythropoietic therapies may 57 androgen excess 57 neonatal herpes 57 Pandemic Influenza H#N# 57 CIN2 57 HCV genotypes 57 BRCA1 mutation carriers 57 genital HPV infection 57 influenza outbreaks 57 CIN2 + 57 hypoglycaemic episodes 57 injectible vaccine 57 genital lesions 57 BMPR2 57 Plasmodium falciparum malaria 57 sonographic diagnosis 57 HbF 57 whooping cough pertussis 57 rotavirus infections 57 hypersensitivity reaction 57 EpCAM expression 57 acute rheumatic fever 57 HBV infection 57 vaccine Menactra 57 Havrix 57 quinolone antibiotics 57 Infusion reactions 57 μg dL 57 gastrointestinal toxicity 57 diphtheria pertussis tetanus 57 subclinical hypothyroidism 57 mycophenolate mofetil 57 hypovitaminosis D 57 ALT elevation 57 #OHD levels 57 acellular pertussis 57 Staphylococcus aureus MRSA 57 valent pneumococcal conjugate vaccine 57 immunocompetent 57 asymptomatic PAD 57 Pertussis vaccine 57 Urinary tract infections UTIs 57 ADPKD 57 hypomagnesemia 57 RSV prophylaxis 57 Ixiaro 57 DMARDS 57 vancomycin resistant 57 meningococcal conjugate 57 unknown etiology 57 tolterodine ER 57 abnormal mammograms 57 de ath 57 dosage regimens 57 invasive carcinoma 57 urticaria hives 57 cranial radiation 57 locoregional recurrence 57 type 1diabetes 57 CCyR 57 nonfatal MI 57 varicella zoster virus VZV 57 anemia neutropenia 57 tetravalent vaccine 57 events TEAEs 57 Haemophilus Influenzae 57 Streptococcus pneumonia 57 MAGE A3 ASCI 57 virological response 57 PPCM 57 Kinoid 57 Thrombotic events 57 Hiberix 57 viremia 57 anticonvulsant medications 57 C. difficile colitis 57 venlafaxine XR 57 immunologic responses 57 Measles mumps 56 lopinavir r arm 56 underwent CABG 56 iron supplementation 56 Mycoplasma pneumoniae 56 Adjuvant chemotherapy 56 enalapril 56 lung cancer NSCLC 56 cisplatin chemotherapy 56 CIMZIA ™ 56 viral subtypes 56 recurrent metastatic 56 viral respiratory infections 56 tetanus pertussis 56 streptococcus pneumoniae 56 distant metastases 56 neuropsychiatric adverse 56 postoperative AF 56 TOPAMAX ® 56 microalbumin test 56 HER2 expression 56 neutralizing antibody 56 receiving antiretroviral therapy 56 comorbid illnesses 56 hemorrhagic strokes 56 endometriosis ovarian cysts 56 VaD 56 Recurrences 56 inhalational anthrax 56 nonadherence 56 seropositive patients 56 hepatitis B vaccination 56 achieved sustained virological 56 timepoints 56 VLBW infants 56 CR nPR 56 chlorambucil 56 acid suppressive drugs 56 pertussis immunizations 56 pertussis DTaP 56 swab specimens 56 bronchopulmonary dysplasia 56 squamous histology 56 HBV vaccine 56 colorectal bowel 56 receiving SIMPONI 56 viremic 56 GI bleeds 56 epithelial tumors 56 latent celiac disease 56 Neisseria meningitidis serogroups 56 B streptococcal 56 APOE e4 56 plasma folate 56 revascularization procedures 56 non squamous NSCLC 56 retrograde ejaculation 56 necrotizing pancreatitis 56 febrile illnesses 56 vesicoureteral reflux 56 valacyclovir 56 DVT PE 56 thromboembolic events 56 ximelagatran 56 herpes zoster 56 prior chemotherapy regimens 56 equine WNV 56 zoster 56 Flu Mist nasal spray 56 postoperative mortality 56 hematologic abnormalities 56 Guillain Barre Syndrome GBS 56 multidose vials 56 Heavy menstrual bleeding 56 neutropenic patients 56 ROTATEQ 56 chlamydia infections 56 nonmelanoma skin cancer 56 hormone receptor negative 56 adjuvanted H#N# 56 hepatitis B vaccinations 56 bilirubin levels 56 Guillain Barré syndrome 56 postoperative morbidity 56 reoperations 56 pT3 56 Chlamydia trachomatis infection 56 serum homocysteine 56 preterm newborns 56 fatal anaphylactic 56 Chlamydia pneumoniae 56 underdiagnosis 56 etiologic agent 56 Dr. Ramilo 56 ICD implants 56 varicella vaccination 56 GBMs 56 renal cell carcinomas 56 H#N# influenza vaccines 56 adverse reactions incidence 56 ICD shocks 56 A1c levels 56 ZYVOX 56 deep venous thromboses 56 simplex virus 56 food induced anaphylaxis 56 angioedema 56 teratogenic 56 vulvar cancer 56 SAEs 56 HSV2 56 VFEND 56 Venous thromboembolism 56 mg/m2 dose 56 inflammatory biomarkers 56 metastatic malignant melanoma 56 Hb A1C 56 atopic 56 CHDs 56 systemic toxicity 56 urticaria 56 hypoglycemic events 56 immunodeficient 56 histologically confirmed 56 Dermatologic Toxicity Dermatologic toxicities 56 Stent thrombosis 56 nitrofurantoin 56 chronic HCV infection 56 bacterial respiratory infections 56 oxcarbazepine 56 MMSE scores 56 dengue haemorrhagic fever 56 Enterobacter cloacae 56 Campylobacter infections 56 riociguat 56 hematological adverse 56 baseline LDH 56 paroxetine Paxil 56 inactivated poliovirus vaccine 56 KRAS status 56 TNF blocker therapy 56 diphtheria pertussis whooping cough 56 Altastaph 56 bowel polyps 56 mRCC 56 baseline HbA1c 56 seasonal influenza vaccination 56 urethritis 56 ASCUS 56 enterovirus infections 56 haloperidol Haldol 56 lipid lowering medications 56 cirrhotic patients 56 vaginal hysterectomy 56 HPA axis suppression 56 experienced virologic failure 56 nephrotoxicity 56 cidofovir 56 enterococcal 56 cranial irradiation 56 rhinosinusitis 56 adrenal suppression 56 confidence interval #.#-#.# 56 virus RSV 56 cytopenias 56 Telithromycin 56 Menveo 56 GRNOPC1 cells 56 proliferative diabetic retinopathy 56 unadjuvanted vaccines 56 Pseudomonas aeruginosa infections 56 neurologic symptoms 56 streptococcal infections 56 plus methotrexate 56 unresectable HCC 56 seroprevalence 56 HIV seronegative 56 C diff infections 56 efalizumab 56 C. trachomatis 56 squamous cell lung cancer 56 MIs 56 parasitaemia 56 cases/# 56 prospectively enrolled 56 Flu Cy 56 latent TB infection 56 vaccine LAIV 56 respiratory viral infections 56 serum IgE 56 Live Attenuated Influenza Vaccine 56 histologically proven 56 needlesticks 56 Relapsing remitting MS 56 spontaneous preterm birth 56 lopinavir 56 cerebrovascular accidents 56 Chlamydia trachomatis 56 syndromic 56 pertussis diphtheria 56 RRMS patients 56 pneumococcal vaccinations 56 G CSFs 56 IPAH 56 unintentional poisoning 56 invasive pneumococcal disease 56 antiandrogens 56 haematologic 56 acute myocardial infarctions 56 trastuzumab Herceptin ® 56 androgen suppression 56 Anaphylactic reactions 56 Respiratory syncytial virus RSV